|
Experimental
NNRTI TMC 120 Appears Safe and Effective as Microbicide
By Brian Boyle, MD
TMC120, a non-nucleoside
reverse transcriptase inhibitor (NNRTI), has demonstrated potent anti-
HIV-1 activity and efficacy in preventing vaginal transmission in
a hu-SCID mouse model. In order to evaluate the potential of TMC120
as a microbicide,
investigators at Tibotec studied it in human cervical explant models.
In the study, anti HIV-1 activity of TMC120 (and formulations) was
assessed by treatment of virus, cells, or human cervical explants
with either base compound or formulated gel. Further, the activity
of TMC120 in physiologically relevant fluid (semen and cervical mucus)
and the effect of TMC 120 on the viability of vaginal epithelial cell
lines and cervical tissue, using Nonoxynol-9 as a control, and the
effects of TMC120 on cytokine expression were also evaluated.
The investigators found that TMC120 inhibited HIV-1 infection in both
cell based assays and cervical explant models, regardless of the viral
strain (CXCR4 or CCR5). In addition, TMC120, alone and in formulation,
demonstrated excellent biocompatibility with cervical tissue, induced
little or no modulation of cytokine production, and physiologically
relevant fluids (semen and cervical mucus) had no effect on its activity.
Finally, and importantly, due to prolonged drug tissue levels, TMC-120
demonstrated significant anti-HIV memory effects, with cervical tissue
resisting viral challenge up to 6 days post treatment (2 hours) with
TMC120.
Based
on these data the authors conclude, “TMC120 demonstrates good anti-viral
activity in cellular and cervical explant models, and shows no toxicity
at therapeutic levels. These data suggest TMC120 represents a promising
candidate microbicide.”
Given
the very slow development of a vaccine, these data are very encouraging
since one prong of prevention efforts should, if possible, include
the availability of microbicides that help prevent transmission.
Although, a safe and effective microbicide has yet to be found,
this study and others have given rise to hope that one becomes available
in the not to distant future.
08/10/05
Reference
S
Harman and others. TMC120 blocks HIV-1 infection in cellular and
human cervical tissue models. Abstract MoPp0105. 3rd
International AIDS Society Conference on HIV Pathogenesis and Treatment.
July 24-27, 2005. Rio de Janeiro, Brazil.
|